Tecvayli (teclistamab-cqyv)

T cell-redirecting therapies represent a central pillar in modern oncology, delivering high response rates across hematologic malignancies with expanding roles in earlier treatment settings. Future progress will depend on improving durability, optimizing sequencing, mitigating toxicity, and enhancing real-world deliverability through next-generation and multitarget platforms.

Patients receiving immunoglobulin replacement therapy had a 2.01 lower risk of infections Grade 3 or 4 and a 6.14 lower risk of death. Our findings demonstrate the efficacy of teclistamab in a heavily diseased and pretreated cohort with AL amyloidosis and highlight the necessity of a concomitant immunoglobulin replacement therapy.

P1/2, N=35, Not yet recruiting, Odense University Hospital

P3, N=1226, Not yet recruiting, University of Leeds

Finally, a reduction in BCMA receptor density was observed on bone marrow tumor plasma cells at relapse. Our data highlight the importance of understanding mechanisms of response, resistance, and relapse to teclistamab to optimize T-cell and bispecific antibody activity, advance dosing and sequencing strategies, and inform further evaluation of teclistamab combinations with other anti-myeloma agents and use in earlier lines of treatment to improve patient outcomes.

P2, N=30, Recruiting, Shanghai Zhongshan Hospital

P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025

P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P1/2, N=40, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed

P2, N=300, Active, not recruiting, Multiple Myeloma Research Consortium | Recruiting --> Active, not recruiting

P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028